GlassScriptPhysician profile
Mark Joseph Lybik
NPI 1184626707
$8,606.87
in general payments reported to CMS, 2019-2025
36 companies · $746 in 2025
The $746 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $764 · 2021: $896 · 2022: $1,522 · 2023: $1,371 · 2024: $2,315 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,910 · Travel and Lodging: $439 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,909.89 |
| Travel and Lodging | $438.73 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,099.33 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $874.45 | 2019-2025 | Entyvio, Gattex |
| Boston Scientific Corporation | $850.13 | 2019-2024 | Acquire |
| Janssen Biotech, INC. | $681.96 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $658.81 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Regeneron Healthcare Solutions, INC. | $418.64 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $270.54 | 2019-2025 | |
| Lilly USA, LLC | $204.28 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $176.19 | 2022-2024 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $173.88 | 2024-2025 | Voquezna |
| Celgene Corporation | $169.46 | 2021-2024 | Zeposia |
| Genzyme Corporation | $165.92 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $162.33 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $138.23 | 2021-2024 | Linzess |
| Madrigal Pharmaceuticals | $63.31 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $54.78 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $40.05 | 2022-2025 | Ocaliva |
| Aimmune Therapeutics, INC. | $37.12 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $35.89 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $28.57 | 2020 | |
| Amgen INC. | $28.29 | 2020 | |
| Organon LLC | $27.86 | 2022 | |
| Daiichi Sankyo INC. | $25.80 | 2019-2022 | |
| Redhill Biopharma INC. | $24.97 | 2020 | |
| Ferring Pharmaceuticals INC. | $21.24 | 2023 | Rebyota |
| Pfizer INC. | $19.86 | 2020 | |
| Ardelyx, INC. | $19.78 | 2023 | Ibsrela |
| Shire North American Group INC | $19.42 | 2019 | |
| Vivus LLC | $16.95 | 2024 | Pancreaze |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.31 | 2023 | Cyltezo |
| Ucb, INC. | $15.46 | 2023 | Cimzia |
| Romark Laboratories, Lc | $15.22 | 2020 | |
| Merck Sharp & Dohme LLC | $14.69 | 2022 | |
| Fresenius Kabi USA, LLC | $13.54 | 2023 | Idacio |
| Evoke Pharma, INC. | $12.61 | 2021 | |
| Olympus America INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lybik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.